$260,000.00 in Sales Expected for Autolus Therapeutics plc (NASDAQ:AUTL) This Quarter

Equities research analysts predict that Autolus Therapeutics plc (NASDAQ:AUTL – Get Rating) will post $260,000.00 in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Autolus Therapeutics’ earnings, with the lowest sales estimate coming in at $220,000.00 and the highest estimate coming in at $300,000.00. Autolus Therapeutics reported sales of $1.65 million in the same quarter last year, which indicates a negative year over year growth rate of 84.2%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Autolus Therapeutics will report full-year sales of $940,000.00 for the current year, with estimates ranging from $870,000.00 to $1.00 million. For the next financial year, analysts forecast that the business will report sales of $4.12 million, with estimates ranging from $1.00 million to $8.70 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Autolus Therapeutics.

Autolus Therapeutics (NASDAQ:AUTL – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.10. Autolus Therapeutics had a negative net margin of 6,098.54% and a negative return on equity of 49.80%. During the same quarter in the prior year, the company posted ($0.53) earnings per share.

AUTL has been the topic of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a research note on Thursday, March 10th. Zacks Investment Research cut shares of Autolus Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, February 21st. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Autolus Therapeutics presently has an average rating of “Buy” and an average price target of $11.75.

NASDAQ:AUTL opened at $2.84 on Friday. Autolus Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $8.23. The stock has a market cap of $258.18 million, a PE ratio of -1.43 and a beta of 1.60. The firm’s fifty day simple moving average is $3.89 and its 200-day simple moving average is $4.78.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. LGT Capital Partners LTD. acquired a new stake in Autolus Therapeutics in the 1st quarter valued at about $2,085,000. BlackRock Inc. grew its stake in Autolus Therapeutics by 214.5% in the 4th quarter. BlackRock Inc. now owns 471,733 shares of the company’s stock valued at $2,448,000 after acquiring an additional 321,761 shares during the last quarter. Woodline Partners LP purchased a new position in Autolus Therapeutics in the 4th quarter valued at about $4,868,000. Goldman Sachs Group Inc. lifted its holdings in Autolus Therapeutics by 172.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 153,421 shares of the company’s stock valued at $796,000 after purchasing an additional 97,030 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Autolus Therapeutics in the 4th quarter valued at about $88,000. 61.45% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile (Get Rating)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.

Further Reading